Dublin, Ohio-based DASI Simulations – a medical technology start-up offering a novel AI-powered medical platforms to advance toward lifetime management and improved outcomes for structural heart interventions – announced it has closed it $5 million convertible note round. The company has now surpassed $7 million in funds raised.
DASI will utilize the funds to continue to commercialize and extend its initial product, PrecisionTAVI, and launch new AI-driven products in the structural heart domain.
DASI’s Simulations technology is a novel AI-powered medical platform that transforms routine imaging (CT, MRI, etc.) into an interactive four-dimensional (4D) predictive environment accessible on mobile, tablet, or web browsers. And this technology solves the current problem where physicians rely on highly manual planning steps on images without the ability to predict whether a treatment will work or not.
Through the company’s predictive interactive platform, physicians can visualize in 4D how different devices interact with the patient’s unique anatomy and get insights into complication risks as well as plan patient’s future interventions.
KEY QUOTES:
“We are thrilled by the unwavering confidence shown by our investors, both in our company and in our growing portfolio of products. Our momentum has been nothing short of extraordinary since receiving FDA clearance for PrecisionTAVI last May and CMS reimbursement in November.”
“The closing of the funding round has set DASI Simulations on an upward trajectory for continued success in 2024 with revenue growth, brand development, additional intellectual property, and strategic partnerships.”
- Teri Sirset, co-founder and CEO
“We have built significant momentum towards becoming the standard-of-care for structural heart procedures.”
“Clinical studies conducted with the AI-powered DASI technology, coupled with cutting-edge computational modeling, have consistently demonstrated substantial improvements in patient outcomes. By reducing complications and decreasing costs, DASI Simulations is driving a transformation in the healthcare landscape.”
- Dr. Lakshmi (Prasad) Dasi, co-founder and Chief Science & Technology Officer
